AXSM - Axsome Therapeutics GAAP EPS of -$2.08 misses by $0.92 revenue of $71.53M beats by $2.49M
2024-02-20 07:10:40 ET
More on Axsome Therapeutics
- Axsome: Show Me Another Company With Such A Stack Of Catalysts
- Axsome Therapeutics: Positive Q3, We Like The Launch Success Story
- Axsome Therapeutics Q4 2023 Earnings Preview
- UBS starts Axsome at buy, sees Auvelity hitting $1B sales by 2030
- Seeking Alpha’s Quant Rating on Axsome Therapeutics